2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Yuanquan Yang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma | Phase 2 | Recruiting | Yuanquan Yang | 24 | 2024-12-30 | 2026-10-01 |
| Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody, Biopsy - Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | Yuanquan Yang | 40 | 2024-07-09 | 2026-09-28 |
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Biopsy (1) · Cystectomy (1) · Disulfides (1) · Immunoglobulin G (1) · durvalumab (1) · futibatinib (1) · siltuximab (1) · spartalizumab (1)
United States (2)